At Lykos, formerly MAPS PBC, our mission is to transform mental health care. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain committed to the rigorous pursuit of evidence-based development of novel approaches. Founded in 2014 by the non-profit MAPS, Lykos Therapeutics is a for-profit public benefit corporation ("PBC") established to further the development of investigational psychedelic-assisted therapies. As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is viewed through a public benefit lens.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
01/05/24	$100,000,000	Series A	Alexandra Cohen Foundation Bail Capital Eir Therapeutics Helena Joe and Sandy Samberg Foundation Satori Neuro True Ventures Unlikely Collaborators Foundation Vine Ventures	undisclosed